MR imaging in patients at risk for developing nephrogenic systemic fibrosis: protocols, practices, and imaging techniques to maximize patient safety.

Nephrogenic systemic fibrosis (NSF) is a rare but potentially debilitating or even fatal fibrosing condition that most often affects the skin but is now also recognized to involve multiple organs. The first report on NSF was published in 1997, and there is mounting evidence that this condition is associated with renal failure and the administration of large amounts of gadolinium. Although gadolinium-enhanced magnetic resonance (MR) imaging was once considered one of the safer imaging procedures, concerns over NSF have led the radiology community to rethink its imaging practices. Several noncontrast angiographic techniques based on fast spin-echo, gradient-echo, phase-contrast, and inversion-recovery principles are currently available. These techniques allow MR angiography to be performed safely, even in patients at risk for developing NSF. When use of gadolinium-based contrast material is necessary for diagnosis, it is possible to reduce total gadolinium administration through the use of agents with higher relaxivity, time-resolved imaging, high-field-strength magnets, and body compression devices. Management of NSF also requires an understanding of the risk factors of this disease and developing an institutional policy for identifying and testing at-risk patients.

[1]  H. Schmitt-Willich Stability of linear and macrocyclic gadolinium based contrast agents. , 2007, The British journal of radiology.

[2]  Shao-Pow Lin,et al.  MR contrast agents: Physical and pharmacologic basics , 2007, Journal of magnetic resonance imaging : JMRI.

[3]  Gerald A Kirk,et al.  Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. , 2007, AJR. American journal of roentgenology.

[4]  S. Cowper,et al.  Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. , 2007, Journal of the American Academy of Dermatology.

[5]  E. Yucel,et al.  A Summary of Safety of Gadofosveset (MS-325) at 0.03 mmol/kg Body Weight Dose: Phase II and Phase III Clinical Trials Data , 2006, Investigative radiology.

[6]  Lone Skov,et al.  Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. , 2006, Journal of the American Society of Nephrology : JASN.

[7]  Yoshiaki Tanaka,et al.  Dialyzability of gadodiamide in hemodialysis patients , 2006, Radiation Medicine.

[8]  Sophie Laurent,et al.  Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents. , 2006, Contrast media & molecular imaging.

[9]  T. Grobner Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[10]  R. Prayson,et al.  Multiorgan involvement in nephrogenic fibrosing dermopathy: an autopsy case and review of the literature. , 2006, Archives of pathology & laboratory medicine.

[11]  R. Elenitsas,et al.  Histopathologic comparison of nephrogenic fibrosing dermopathy and scleromyxedema , 2005, Journal of cutaneous pathology.

[12]  S. Jimenez,et al.  Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin. , 2004, Arthritis and rheumatism.

[13]  S. Cowper Nephrogenic fibrosing dermopathy: the first 6 years , 2003, Current opinion in rheumatology.

[14]  D. Cohen,et al.  Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease). , 2003, Journal of the American Academy of Dermatology.

[15]  M. Lockhart,et al.  Imaging of adrenal masses. , 2002, European journal of radiology.

[16]  P. Leboit,et al.  Nephrogenic Fibrosing Dermopathy , 2001, The American Journal of dermatopathology.

[17]  P. Leboit,et al.  Scleromyxoedema-like cutaneous diseases in renal-dialysis patients , 2000, The Lancet.

[18]  L. Schad,et al.  Elimination of gadolinium-DTPA by peritoneal dialysis. , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[19]  M. Taupitz,et al.  Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. , 1995, Radiology.